Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Cartesian Therapeutics to post earnings of ($0.80) per share and revenue of $0.10 million for the quarter.
NASDAQ:RNAC opened at $18.03 on Thursday. The stock has a market capitalization of $458.23 million, a PE ratio of -0.34 and a beta of 0.61. Cartesian Therapeutics has a fifty-two week low of $11.67 and a fifty-two week high of $41.87. The company has a fifty day moving average of $18.78 and a two-hundred day moving average of $18.41.
RNAC has been the subject of several research analyst reports. Needham & Company LLC restated a "buy" rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research report on Monday, January 27th. HC Wainwright restated a "buy" rating and issued a $45.00 target price on shares of Cartesian Therapeutics in a research report on Tuesday, January 28th. Cantor Fitzgerald raised Cartesian Therapeutics to a "hold" rating in a research note on Monday, December 2nd. Finally, BTIG Research assumed coverage on Cartesian Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $42.00 price objective for the company. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Cartesian Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $42.86.
View Our Latest Research Report on RNAC
In other Cartesian Therapeutics news, CTO Metin Kurtoglu sold 2,458 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $16.83, for a total value of $41,368.14. Following the completion of the sale, the chief technology officer now directly owns 62,258 shares in the company, valued at $1,047,802.14. This represents a 3.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Blaine Davis sold 3,961 shares of the firm's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $16.72, for a total value of $66,227.92. Following the completion of the sale, the chief financial officer now directly owns 98,839 shares of the company's stock, valued at $1,652,588.08. This trade represents a 3.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,744 shares of company stock valued at $247,337. 57.90% of the stock is currently owned by insiders.
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cartesian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.
While Cartesian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.